<DOC>
	<DOCNO>NCT00005635</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , trastuzumab , locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining monoclonal antibody therapy chemotherapy may kill tumor cell . PURPOSE : Randomized phase II trial study effectiveness two different regimen trastuzumab plus paclitaxel treat woman metastatic breast cancer overexpresses HER2 .</brief_summary>
	<brief_title>Trastuzumab Plus Paclitaxel Treating Women With Metastatic Breast Cancer That Overexpresses HER2</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate safety tolerability subcutaneous trastuzumab ( Herceptin ) plus paclitaxel woman HER2 overexpressing metastatic breast cancer . II . Assess activity treatment regimen patient . III . Determine pharmacokinetics trastuzumab paclitaxel regimen . OUTLINE : This randomize , open label , multicenter study . Patients randomize one two treatment arm . Patients receive load dose trastuzumab ( Herceptin ) IV 90 minute follow paclitaxel IV 3 hour day 0 . Paclitaxel repeat every 3 week 6 course absence disease progression unacceptable toxicity . Arm I : Patients receive trastuzumab subcutaneously ( SC ) weekly start day 7 . Arm II : Patients receive trastuzumab SC twice weekly start day 7 . Treatment trastuzumab SC continue 48 week absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 80 patient ( 40 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : HER2 overexpressing ( 3+ ) metastatic breast cancer immunohistochemistry , amplify fluorescent situ hybridization ( FISH ) No prior chemotherapy breast cancer metastases No bilateral disease Bidimensionally measurable disease At least 1 target lesion great 1 cm2 No significant lymphedema arm ipsilateral mastectomy site , unless patient indwelling catheter purpose chemotherapy infusion No CNS metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Hemoglobin least 9.0 g/dL WBC least 3,000/mm3 Platelet count least 100,000/mm3 Granulocyte count least 1,500/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) ALT , AST , alkaline phosphatase great 2.5 time ULN ( great 4.0 time ULN liver bone metastasis ) Renal : Creatinine great 1.5 time ULN Cardiovascular : No clinically significant cardiovascular disease ( e.g. , uncontrolled hypertension , myocardial infarction , unstable angina , intractable arrhythmia , congestive heart failure , New York Heart Association class IIIV heart disease ) Left ventricular ejection fraction least 50 % low limit normal , whichever low Other : No severe hypersensitivity product contain Cremophor EL ( e.g. , cyclosporine teniposide injection concentrate ) No serious medical condition would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 14 day since prior immunotherapy No prior trastuzumab ( Herceptin ) No concurrent immunotherapy Chemotherapy : See Disease Characteristics Prior cytotoxic chemotherapy allow adjuvant set Prior cumulative doxorubicin exposure great 300 mg/m2 At least 1 year since prior taxane therapy No concurrent chemotherapy Endocrine therapy : At least 14 day since prior hormonal therapy No concurrent hormonal therapy ( e.g. , tamoxifen , megestrol acetate , fluoxymesterone , aminoglutethimide ) Radiotherapy : At least 14 day since prior radiotherapy No concurrent radiotherapy target lesion Surgery : Not specify Other : At least 30 day since prior investigational agent procedure No concurrent investigational agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>